- Home
- HE vs BCRX Comparison
HE vs BCRX Comparison
Compare HE & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HE
- BCRX
- Stock Information
- Founded
- HE 1891
- BCRX 1986
- Country
- HE United States
- BCRX United States
- Employees
- HE N/A
- BCRX N/A
- Industry
- HE Electric Utilities: Central
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HE Utilities
- BCRX Health Care
- Exchange
- HE Nasdaq
- BCRX Nasdaq
- Market Cap
- HE 1.9B
- BCRX 1.6B
- IPO Year
- HE N/A
- BCRX 1994
- Fundamental
- Price
- HE $10.90
- BCRX $7.71
- Analyst Decision
- HE Hold
- BCRX Buy
- Analyst Count
- HE 4
- BCRX 6
- Target Price
- HE $11.00
- BCRX $15.67
- AVG Volume (30 Days)
- HE 3.6M
- BCRX 4.4M
- Earning Date
- HE 05-09-2025
- BCRX 05-05-2025
- Dividend Yield
- HE N/A
- BCRX N/A
- EPS Growth
- HE N/A
- BCRX N/A
- EPS
- HE N/A
- BCRX N/A
- Revenue
- HE $3,219,850,000.00
- BCRX $450,712,000.00
- Revenue This Year
- HE $13.45
- BCRX $27.66
- Revenue Next Year
- HE $1.70
- BCRX $13.59
- P/E Ratio
- HE N/A
- BCRX N/A
- Revenue Growth
- HE N/A
- BCRX 36.00
- 52 Week Low
- HE $7.61
- BCRX $4.03
- 52 Week High
- HE $18.19
- BCRX $9.50
- Technical
- Relative Strength Index (RSI)
- HE 55.98
- BCRX 40.59
- Support Level
- HE $10.25
- BCRX $7.20
- Resistance Level
- HE $11.99
- BCRX $8.80
- Average True Range (ATR)
- HE 0.52
- BCRX 0.45
- MACD
- HE -0.01
- BCRX -0.15
- Stochastic Oscillator
- HE 41.13
- BCRX 22.17
About HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the five islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.